News
Prime Medicine stock nears breakout as FDA clears first human trial
Prime Medicine (PRME) received FDA clearance to begin its first human trial for alpha-1 antitrypsin deficiency, with early data expected in 2027. The company previously reported first clinical data on prime editing in May 2025. PRME trades around $4, with a market cap just under $1 billion, and faces resistance near $4.50, a level that could trigger a sharp move if broken. Volatility is at a 4‑year low, suggesting energy buildup. A free online event on Thursday at 1 p.m. ET will demonstrate the 10x Portfolio strategy.